Latest Earnings Predictions for NeoGenomics Investors in 2025
Understanding Earnings Expectations for NeoGenomics
NeoGenomics NEO is gearing up for its quarterly earnings report, and there’s a buzz in the investment community. Investors are keen to understand the implications of the upcoming announcement and the potential market response.
Analysts' Predictions on Earnings per Share
Analysts anticipate NeoGenomics will report an earnings per share (EPS) of $-0.01. This expectation places a heavy spotlight on the upcoming earnings report, marking it as a pivotal moment for the company.
Market Sentiment Before the Announcement
As anticipation builds, investors are hoping for news that exceeds current estimates while also providing optimistic guidance for the next quarter. Knowing that market reactions are frequently shaped by guidance, this earnings report becomes critically important for stakeholders.
Reviewing Historical Earnings Performance
Recent EPS Trends
In the previous quarter, NeoGenomics surprised analysts with an EPS beat by $0.01, although this was followed by a 2.81% decline in share price the day after the announcement. This showcases the unpredictable nature of investor reactions.
Performance Snapshot
Let’s reflect on how NeoGenomics has performed in prior quarters and the subsequent impact on share prices:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|
| EPS Estimate | -0.01 | -0.01 | 0.03 | 0.01 | 0 |
| EPS Actual | 0.03 | 0 | 0.04 | 0.05 | 0.03 |
| Price Change % | -3.0% | -3.0% | 3.0% | 4.0% | 18.0% |
Monitoring Stock Performance
As of recent trading sessions, shares of NeoGenomics were at $5.8, showing a significant decrease of 65.08% over the past 52 weeks. Such poor returns can understandably lead to disappointment among long-term shareholders.
Insights from Industry Analysts
It is essential for investors to grasp the current market sentiments regarding NeoGenomics. With three analyst ratings, the stock holds a consensus rating of Buy, and the average one-year price target sits at $9.0, indicating potential growth of approximately 55.17%.
Comparative Analyst Ratings with Peers
Analysts have evaluated other notable companies in the healthcare sector to provide a clearer picture.
- AMN Healthcare Services: Analysts lean towards a Neutral rating, predicting a $23.75 target, suggesting a potential upside of 309.48%.
- Fulgent Genetics: Showcases a Buy rating with an average price target of $25.5, reflecting an anticipated upside of 339.66%.
- Pennant Gr: Also rated Neutral with a target of $31.33, indicating an impressive upside of 440.17%.
Summary of Peer Performance
The comparative analysis of key metrics sheds light on the competitive landscape:
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| NeoGenomics | Buy | 10.23% | $77.26M | -5.18% |
| AMN Healthcare Services | Neutral | -16.00% | $198.12M | -0.15% |
| Fulgent Genetics | Buy | 15.17% | $34.44M | -1.69% |
| Pennant Gr | Neutral | 30.08% | $30.30M | 2.30% |
NeoGenomics leads in Revenue Growth at 10.23%, but it struggles with a Gross Profit of $77.26M and a Return on Equity of -5.18%.
About NeoGenomics
NeoGenomics Inc specializes in oncology diagnostic testing and related consultative services. The company operates numerous cancer-focused testing facilities across regions, indicating its comprehensive approach to clinical cancer assessment.
A Closer Look at Financial Metrics
NeoGenomics struggles with market capitalization compared to its peers, partly due to growth outlook or operational challenges.
Revenue Growth Insights
With a reported revenue growth rate of 10.23%, NeoGenomics demonstrates strong sales momentum, despite trailing behind some industry benchmarks.
Profitability Metrics
The company's net margin stands at -24.87%, revealing potential difficulty in cost management. Additionally, with an ROE of -5.18%, NeoGenomics shows challenges in capital efficiency.
Asset Utilization
The ROA of NeoGenomics indicates room for improvement in generating returns from assets, currently at -3.01%. With a debt-to-equity ratio of 0.48, the firm displays prudent financial management.
Frequently Asked Questions
What is NeoGenomics expected to report in its upcoming earnings announcement?
Analysts predict an earnings per share (EPS) of $-0.01 for NeoGenomics.
How has NeoGenomics historically performed in earnings?
NeoGenomics reported an EPS beat last quarter, but the stock dropped by 2.81% the following day.
What is the current share price of NeoGenomics?
As of the latest trading session, shares are priced at $5.8.
What do analysts think about NeoGenomics?
The stock has an overall Buy rating from analysts with a one-year price target of $9.0, implying a potential upside.
How does NeoGenomics compare to its peers?
While NeoGenomics leads in revenue growth among peers, it faces challenges in profitability metrics like gross profit and return on equity.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
